The deal gives J&J access to a pipeline of drugs designed to “hold and kill” tumors, led by a prostate cancer medicine that’s ...

Artios Pharma, which looking for newer targets that, like PARP inhibitors, affect the way tumors fix themselves, said its ...

Clinical trials are more connected and more closely examined than ever. Inspection readiness isn’t a last-minute document ...

The startup, which is backed by a dozen investors including Merck & Co., claims its novel “linkers” can help address some of ...

The new fund will mostly support biotechs making new drugs, with investments spanning from initial financings to follow-on ...

Korro’s lead program for alpha-1 antitrypsin deficiency wasn’t as potent as anticipated, leading the company to change course ...

Elevidys now has a “boxed” warning and is no longer available for Duchenne patients who can’t walk. Elsewhere, Nuvalent and Zymeworks unveiled data for targeted cancer drugs.

After multiple clinical setbacks and layoff rounds, Mersana accepted an offer in which the bulk of the payouts will only ...

Now in a tug of war with Lundbeck, Alkermes could either lose out on a marketed sleepiness drug or end up paying ...

The treatment — which could be the first novel antimalarial in decades — showed the ability in testing to combat drug ...

Pfizer quickly consummated the $10 billion buyout after one-upping Novo Nordisk. Elsewhere, Lundbeck submitted a rival offer for Avadel Pharmaceuticals and Zealand Pharma dropped an obesity drug.

The deal, one of two multibillion-dollar buyouts from Merck this year, centers around a drug that could become an alternative ...